Evidence map›Paper›PMID 21328246›Full record

SynthesisThe Cochrane database of systematic reviews2011

Vitamin E for neuroleptic-induced tardive dyskinesia.

Karla Soares-Weiser, Nicola Maayan, John McGrath

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 13 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 13 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Treatment Recommendations for Tardive Dyskinesia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2019
    Pooled it
  2. Calcium channel blockers for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Cholinergic medication for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Pooled it
  6. Natural Medicines for Psychotic Disorders: A Systematic Review.The Journal of nervous and mental disease · 2018
    Pooled it
  7. Benzodiazepines for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  8. Pooled it
  9. Anticholinergic medication for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  10. Vitamin E for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018
    Pooled it
  11. Pooled it
  12. Antioxidant treatments for schizophrenia.The Cochrane database of systematic reviews · 2016
    Pooled it
  13. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2015
    Pooled it
  14. Trial
  15. Review
  16. Tardive Dyskinesia: Treatment Update.Current neurology and neuroscience reports · 2019
    Review
  17. The Assessment and Treatment of Antipsychotic-Induced Akathisia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2018
    Article
  18. Management of common adverse effects of antipsychotic medications.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Karla Soares-WeiserEnhance Reviews Ltd, John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford, UK, OX4 4GP.
Nicola Maayan
John McGrath
Kleijnen Systematic Reviews (United Kingdom) · GBUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Vitamin E has been proposed as a treatment to prevent or decrease TD.

objectivesTo determine the effects of vitamin E for people with schizophrenia or other chronic mental illnesses who also developed neuroleptic-induced TD. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (March 2010), inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We included reports if they were controlled trials dealing with people with neuroleptic-induced TD and schizophrenia who had been randomly allocated to either vitamin E or to a placebo or no intervention. DATA COLLECTION AND ANALYSIS: We independently extracted data from these trials and we estimated risk ratios (RR) or mean differences (MD), with 95% confidence intervals (CI). We assumed that people who dropped out had no improvement. MAIN

resultsThe review now includes 11 poorly reported randomised trials (total 427 people). There was no clear difference between vitamin E and placebo for the outcome of 'clinically relevant improvement in TD' (6 trials, 256 people, RR 0.95 CI 0.89 to 1.02). For the outcome of 'any improvement in TD symptoms', again, we found no clear difference between groups (7 trials, 311 people, RR 0.86 CI 0.75 to 1.00). However, people allocated to placebo showed more deterioration of their symptoms compared with those given vitamin E (5 trials, 98 people, RR 0.38 CI 0.16 to 0.9). There was no difference in the incidence of adverse effects (9 trials, 203 people, RR 1.29 CI 0.51 to 3.24) or leaving the study early (medium term 6 trials, 173 people, RR 1.29 CI 0.72 to 2.3). There is no trial-based information regarding the effect of vitamin E for those with early onset of TD. AUTHORS'

conclusionsSmall trials of limited quality suggest that vitamin E may protect against deterioration of TD. There is no evidence that vitamin E improves symptoms of this problematic and disfiguring condition once established. New and better trials are indicated in this under-researched area, and, of the many adjunctive treatments that have been given for TD, vitamin E would be a good choice for further evaluation.

Indexed as

Antipsychotic AgentsDyskinesia, Drug-InducedHumansPsychotic DisordersRandomized Controlled Trials as TopicSchizophreniaVitamin EVitaminsAntipsychotic AgentsVitamin EVitamins

Identifiers

PMID21328246
OpenAlexW2142781514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.